Newswise (Oct. 25) – This study identifies a beneficial subset of T cells for fungal vaccine immunity that bolsters efforts to develop a vaccine platform containing suitable adjuvants to potentiate such a T cell subset. “In line with this, we have identified a functional phenotypic marker that could be targeted to enhance this subset to augment vaccine efficacy,” said Dr. Som Nanjappa, an author of the article that appeared in Cell Reports.
Also in:
Genetic Engineering & Biotechnology News (Oct. 27)